Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
RESEARCH TOOLSreports
Holding ALLO?
Track your performance easily
Allogene Therapeutics (ALLO) Ownership Overview
10.22% Insiders
28.58% Mutual Funds
27.66% Other Institutional Investors
10.96% ETFs
22.59% Public Companies and Individual Investors
The ownership structure of Allogene Therapeutics (ALLO) stock is a mix of institutional, retail, and individual investors. Approximately 67.19% of the company’s stock is owned by Institutional Investors, 10.22% is owned by Insiders, and 22.59% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
| Dec 10, 2024 | Deborah M. Messemer Director | xxxxxxxxxxxxx | $19916 |
| Dec 09, 2024 | Franz Humer Director | xxxxxxxxxxxxx | $19917 |
| Jun 03, 2024 | Franz Humer Director | xxxxxxxxxxxxx | $26096 |
| May 20, 2024 | Arie Belldegrun Director | xxxxxxxxxxxxx | $4999997 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
| Sep 30, 2024 | xxxxxxxxxxxxx | $677885 | |
| Sep 30, 2024 | xxxxxxxxxxxxx | $12220040 | |
| Sep 30, 2024 | xxxxxxxxxxxxx | $15871128 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 10,099,279 | Insider | 4.82% | 21,511,464 | |
| 7,931,219 | Institution | 3.78% | 16,893,496 | |
| 7,723,302 | Insider | 3.68% | 16,450,633 | |
| 7,035,377 | Institution | 3.36% | 14,985,353 | |
| 6,896,552 | Institution | 3.29% | 14,689,656 | |
| 6,809,004 | Institution | 3.25% | 14,503,179 | |
| 6,484,222 | Institution | 3.09% | 13,811,393 | |
| 5,772,200 | Institution | 2.75% | 12,294,786 | |
| 5,668,260 | Institution | 2.70% | 12,073,394 | |
| 5,039,432 | Institution | 2.40% | 10,733,990 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 7,035,377 | Institution | 3.36% | 14,985,353 | |
| 6,896,552 | Institution | 3.29% | 14,689,656 | |
| 6,809,004 | Institution | 3.25% | 14,503,179 | |
| 5,772,200 | Institution | 2.75% | 12,294,786 | |
| 5,039,432 | Institution | 2.40% | 10,733,990 | |
| 4,604,376 | Institution | 2.20% | 9,807,321 | |
| 3,566,079 | Institution | 1.70% | 7,595,748 | |
| 3,461,580 | Institution | 1.65% | 7,373,165 | |
| 2,059,978 | Institution | 0.98% | 4,387,753 | |
| 1,988,965 | Institution | 0.95% | 4,236,495 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 4,337,709 | Institution | 2.07% | 11,082,847 | |
| 4,234,344 | Institution | 2.02% | 8,892,122 | |
| 3,479,810 | Institution | 1.66% | 7,411,995 | |
| 2,461,455 | Institution | 1.17% | 6,289,018 | |
| 1,243,177 | Institution | 0.59% | 2,647,967 | |
| 938,398 | Institution | 0.45% | 1,998,788 | |
| 739,228 | Institution | 0.35% | 1,552,379 | |
| 582,270 | Institution | 0.28% | 1,487,700 | |
| 451,289 | Institution | 0.22% | 1,153,043 | |
| 525,933 | Institution | 0.25% | 1,104,459 |
FAQ
Who Owns Allogene Therapeutics Inc (ALLO)?
According to the latest TipRanks data, approximately 27.66% of the company's stock is held by institutional investors, 10.22% is held by insiders, and 22.59% is held by retail investors.
What percentage of Allogene Therapeutics Inc (ALLO) stock is held by institutional investors?
According to the latest TipRanks data, approximately 27.66% of Allogene Therapeutics Inc (ALLO) stock is held by institutional investors.
What percentage of Allogene Therapeutics Inc (ALLO) stock is held by retail investors?
According to the latest TipRanks data, approximately 22.59% of Allogene Therapeutics Inc (ALLO) stock is held by retail investors.
Who owns the most shares of Allogene Therapeutics Inc (ALLO)?
Arie Belldegrun owns the most shares of Allogene Therapeutics Inc (ALLO).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.